D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

This trial tests two experimental immunotherapy drugs — D2C7-IT and 2141-V11 — delivered directly into the brain tumour through a catheter in patients newly diagnosed with glioblastoma (GBM), the most aggressive type of brain cancer. The drugs are given after completion of standard radiation therapy and chemotherapy. The goal is to test safety and whether these treatments can extend survival. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with glioblastoma (IDH wildtype, MGMT unmethylated, WHO grade 4) - You have completed standard radiation and chemotherapy (TMZ) - Your tumour has some remaining non-enhancing disease but the contrast-enhancing residual tumour is 3 cm or less - Your blood counts and organ function are adequate - You are in good enough health (Karnofsky score > 70%) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have a life-threatening brain herniation - You have an active serious infection, severe heart disease, or uncontrolled diabetes - You have HIV, hepatitis C, or known immunodeficiency - Your tumour involves the brainstem, cerebellum, or both sides of the brain - You are on more than 4 mg per day of dexamethasone (a steroid) within 2 weeks before treatment - You have had prior treatment for your GBM beyond standard surgery and radiation/chemo Talk to your doctor to see if this trial is right for you.